2026-029-01 Bioinformatician
Under the leadership of Josep Tabernero, VHIO is an internationally recognized cancer center. Its multidisciplinary, collaborative model drives scientific progress and innovative cancer treatments.
The Vall d´Hebron Institute of Oncology (VHIO) Seeks a “Cancer Genomics Bioinformatician ”
Reference: 2026-029-01
Application deadline: Until the position is filled
Number of vacancies: 1
Job description:
The Computational Immunogenomics Group is looking for a motivated cancer genomics bioinformatician to join our team. This role offers the opportunity to contribute to translational cancer research projects focused on cancer genomics and tumor–immune interactions, with direct application to clinically relevant questions. The successful candidate will help analyze and interpret large-scale genomics and transcriptomics data and support a range of collaborative projects within the group
Main duties:
Efficiently process and analyze internal and external genomics (WES/WGS) and transcriptomics (RNA-seq) data from patients.
Support genomic and other data-driven analyses across ongoing projects in the lab.
Collaborate closely with team members and clinical collaborators
Requirements:
Degree in bioinformatics, computer science, biological sciences or similar.
Experience of at least 6 months in cancer genomics.
Strong knowledge of Unix operating systems
Fluent in Python and in Bash scripting
Excellent organization skills.
Knowledge of processing and analyzing cancer genomics data (WGS/WES).
Team player.
Good English communication skills.
Experience with Oncoanlyzer pipeline (https://nf-co.re/oncoanalyser/2.3.0/) would be considered a plus.
For recent and relevant publications, you may check: https://vhio.net/biosketch-francisco-martinez-jimenez/ and https://www.franmartinezlab.com/
Additional information:
We offer:
📈The possibility of developing your professional career in a competitive environment.
🧠To be part of a center that is constantly developing, pursuing excellence in research and collaborating with leading teams.
🫱🏻🫲🏾We offer and promote a diverse and inclusive environment, and welcome all people equally, regardless of age, disability, gender, nationality, race, religion or sexual orientation.
🪴We care about our environment and understand the importance of sustainability. We have the GreenVhio program, which you can be a part of.
Conditions:
📝2 year appointment with a possible extension depending on evaluation and funding.
🗓️Full-time position, 37.5 hours per week.
💶Salary according to qualifications and experience following VHIO pay scales.
💳Flexible remuneration program (includes restaurant vouchers/cards, transport, medical insurance, and “baby daycare” voucher).
⏰Flexible working hours and measures to balance work, family, and personal life, and promote gender equality, as established in the VHIO collective agreement.
🗺️24 days of holidays and 6 personal days.
🎓Fully subsidized Catalan, Spanish, or English courses.
🏃➡️Take advantage of doing sports at great prices with Urban Sports Club.
🩺You’ll have access to weekly physiotherapy sessions at the office, offered at a reduced price for the team.
Vall d’Hebron Institute Oncology (VHIO) endorses the Requirements and Principles of the European Charter for Researchers, the Code of Conduct for the Recruitment of Researchers promoted by the European Commission and follows Equal Opportunities policies.
On 10th April 2018 VHIO was awarded the “HR Excellence in Research” logo. Our Institute was consequently granted permission to use the HR Excellence in Research Award logo as demonstration of its stimulating and favourable work environment in line with the Charter & Code.
- Department
- Computational Immunogenomics Group
About VHIO
The Vall d'Hebron Institute of Oncology (VHIO) is a leading center for personalized cancer medicine.
Thanks to its pioneering model of multidisciplinary and translational research, as well as its participation in consortia and projects with other prestigious centers worldwide, it has become one of the most important comprehensive centers in Europe. VHIO is able to rapidly translate the latest laboratory research discoveries into early-phase clinical trials, and thus, into new opportunities for patients.